Short-term efficacy and safety of new biological agents targeting the interleukin-23-T helper 17 pathway for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis

2016 ◽  
Vol 176 (3) ◽  
pp. 594-603 ◽  
Author(s):  
F. Gómez-García ◽  
D. Epstein ◽  
B. Isla-Tejera ◽  
A. Lorente ◽  
A. Vélez García-Nieto ◽  
...  
Keyword(s):  
Systematic Review ◽  
Plaque Psoriasis ◽  
Meta Analysis ◽  
Biological Agents ◽  
Efficacy And Safety ◽  
T Helper ◽  
Short Term ◽  
T Helper 17 ◽  
Severe Plaque Psoriasis ◽  
Interleukin 23

scholarly journals Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials

2019 ◽  
Vol 2019 ◽  
pp. 1-25 ◽  
Author(s):  
Fan Bai ◽  
Gang Gang Li ◽  
Qingmin Liu ◽  
Xinwu Niu ◽  
Ruilian Li ◽  
...  
Keyword(s):  
Adverse Events ◽  
Plaque Psoriasis ◽  
Meta Analysis ◽  
Term Treatment ◽  
Controlled Trials ◽  
Efficacy And Safety ◽  
High Efficacy ◽  
Short Term ◽  
Short Term Treatment ◽  
Severe Plaque Psoriasis

Background. The role of interleukin-12 (IL-12), interleukin-23 (IL-23), and interleukin-17 (IL-17) has been recognized in psoriasis pathogenesis, and new drugs targeting this axis have already been developed which may provide a new therapeutic approach for patients with moderate to severe psoriasis. Objective. To compare the direct and indirect evidences of the efficacy and safety of brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab in the short-term treatment of moderate to severe plaque psoriasis using network meta-analysis (NMA). Methods. A comprehensive literature search was performed in PubMed, EMBASE, and Cochrane Central Register of Controlled Trials for the available relevant studies. NMA was conducted by Stata 15.0 software using relative risks (RR) with 95% confidence interval to assess the clinical effectiveness and safety. Ranked the efficacy and safety for each drug accordance with the surface under the cumulative ranking curve (SUCRA). Results. This meta-analysis included 28 studies. All the interventions performed better than placebo in short-term achievement. Based on the result of SUCRA, ixekizumab 80 mg every 2 weeks ranked the highest in short-term achievement of PASI 75 (SUCRA = 93.0%). Brodalumab 210 mg ranked the highest in short-term achievement of PASI 100 (SUCRA = 85.0%). Secukinumab 300 mg ranked the highest in short-term achievement of sPGA 0/1 or IGA 0/1 or PGA 0/1 (SUCRA = 98.1%). In terms of having a risk of adverse events, the rates were higher in brodalumab, secukinumab, ixekizumab, and ustekinumab 45 mg compared with placebo. Ixekizumab 80 mg every 4 weeks ranked the highest in the risk of adverse events during short-term treatment (SUCRA = 4.5%). Guselkumab 50 mg ranked the highest in the risk of serious adverse events during short-term treatment (SUCRA = 25.9%). Ixekizumab 80 mg every 4 weeks ranked the highest in the risk of discontinuations due to adverse events during short-ter treatment (SUCRA = 10.7%). Conclusions. IL-17, IL-12/23, and IL-23 inhibitors had high efficacy in the achievement of PASI 75, PASI 100, and sPGA 0/1 or IGA 0/1 or PGA 0/1 in moderate to severe plaque psoriasis after 12 or 16 weeks of treatment. IL-17 inhibitors showed superior efficacy. However, its clinical safety was poor. Risankizumab appeared to have relatively high efficacy and low risk. The clinical tolerance of other biological agents needs to be further observed.

scholarly journals Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis

2020 ◽  
Vol 99 (1) ◽  
pp. 53-61 ◽  
Author(s):  
Yayoi Tada ◽  
Rei Watanabe ◽  
Hisashi Noma ◽  
Yasumasa Kanai ◽  
Takanobu Nomura ◽  
...  
Keyword(s):  
Systematic Review ◽  
Plaque Psoriasis ◽  
Meta Analysis ◽  
Short Term ◽  
Severe Plaque Psoriasis

Placebo Response in Phase 3 Trials of Systemic Therapies for Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis

Dermatology ◽  
2020 ◽  
pp. 1-8
Author(s):  
Danni Ambikaibalan ◽  
Anna Sophie Quaade ◽  
Anne-Sofie Halling ◽  
Jacob P. Thyssen ◽  
Alexander Egeberg
Keyword(s):  
Systematic Review ◽  
Plaque Psoriasis ◽  
Meta Analysis ◽  
Placebo Response ◽  
Phase 3 ◽  
Severe Plaque Psoriasis ◽  
Systemic Therapies
Sign in / Sign up

Export Citation Format

Share Document